drugset / Trial / NCT00895245
Fosaprepitant Dimeglumine, Palonosetron Hydrochloride, and Dexamethasone in Preventing Nausea and Vomiting Caused by Cisplatin in Patients With Stage III or Stage IV Head and Neck Cancer Undergoing Chemotherapy and Radiation Therapy
NaSingle-groupOpen-labelSupportive care
Summary
RATIONALE: Fosaprepitant dimeglumine, palonosetron hydrochloride, and dexamethasone may help lessen or prevent nausea and vomiting caused by cisplatin in patients with head and neck cancer undergoing chemotherapy and radiation therapy. PURPOSE: This phase II trial is studying how well fosaprepitant dimeglumine together with palonosetron hydrochloride and dexamethasone works in preventing nausea and vomiting caused by cisplatin in patients with stage III or stage IV head and neck cancer undergoing chemotherapy and radiation therapy.
Timeline
- Start
- 2009-02
- Primary completion
- 2010-09
- Completion
- 2011-02
Outcome
Outcome not reported
Stopped: “Study stopped due to lack of efficacy in first 6 patients”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | fosaprepitant dimeglumine | Unknown | — | Intravenous |
| Background | Cisplatin | Other / unclassified | — | Intravenous |
| Background | Dexamethasone | Small molecule | — | Intravenous |
| Background | Palonosetron | Other / unclassified | — | Intravenous |